Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Those who begin antiretrovirals with a higher CD4 count and CD4 to CD8 ratio are more likely to experience immune recovery.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
The liver virus affects as many as one in four people worldwide.
A considerable proportion of a group of people receiving HIV care had signs of the disease, but only a small group was diagnosed.
In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.
This is according to the large randomized controlled START trial.
A review of some of the the latest research relating to hepatitis B presented at the annual Liver Meeting.
One researcher argues that the pharmaceutical industry ought to pay greater heed to such risks during drug development.
The latest research on hepatitis C treatment for people who are infected with HBV, HCV, and HIV.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
Essential info for anyone who is hepatitis B core antibody-positive, surface antigen-negative, and surface antibody-positive or negative.
Although the risk is low, periodic medical monitoring for liver cancer among those with hepatitis B surface antigen clearance is advised.
Stanford’s Mehlika Toy is working with the World Health Organization to determine what it will take to stop the liver virus in its tracks.
Researchers sought to deduce what drives these symptoms by comparing people with hep C with those who have other liver diseases.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.